Tiziana Life Sciences hosts webcast on Phase 2a foralumab trial results
TLSA•Tiziana Life Sciences scheduled a Nov. 9 webcast to discuss positive Phase 2a INFORM-MS topline results for intranasal foralumab in non-active secondary progressive multiple sclerosis.
1. Webcast and conference
A key opinion leader webcast is scheduled for Nov. 9, 2026, at noon ET / 17:00 GMT to discuss the trial results. CEO Ivor Elrifi will present at BIO-Europe in Cologne on Nov. 10 at 13:45 local time; the company said it is seeking potential strategic partnerships at the event, which runs Nov. 9-11.
